PDCD1 and melanoma: Interestingly, when drugs inhibit the expression of Tyro3, Ax1 and MERTK in vivo, melanoma growth slows down, CD8+T cell infiltration increases, and anti-PD-1 checkpoint inhibitor immunotherapy is enhanced.